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PDZ domain interactions are involved in signaling
and trafficking pathways that coordinate crucial
cellular processes. Alignment-based PDZ binding
motifs identify the few most favorable residues at
certain positions along the peptide backbone. How-
ever, sequences that bind the CAL (CFTR-associated
ligand) PDZ domain reveal only a degenerate motif
that overpredicts the true number of high-affinity in-
teractors. Here, we combine extended peptide-array
motif analysis with biochemical techniques to show
that non-motif ‘‘modulator’’ residues influence CAL
binding. The crystallographic structures of 13 CAL:
peptide complexes reveal defined, but accommoda-
ting stereochemical environments at non-motif posi-
tions, which are reflected in modulator preferences
uncovered by multisequence substitutional arrays.
These preferences facilitate the identification of
high-affinity CAL binding sequences and differen-
tially affect CAL and NHERF PDZ binding. As a result,
they also help determine the specificity of a PDZ
domain network that regulates the trafficking of
CFTR at the apical membrane.
INTRODUCTION
If each residue is uniquely specified, a decapeptide can encode
more than 1013 distinct sequences, providing a versatile and
specific mechanism to encode protein:protein interactions.
Indeed, domains recognizing short linear motif (SLiM) peptides
are found throughout the human genome, including the abun-
dant family of PDZ domains first recognized in the proteins
PSD-95, Dlg, and ZO-1 (Davey et al., 2012; Harris and Lim,
2001; Lee and Zheng, 2010; Nourry et al., 2003). PDZ target in-
teractions are governed by a variety of constraints, including
local concentration, multidentate binding interfaces, and interac-
tions with additional proteins (Luck et al., 2012). Nevertheless,
the recognition of a generally C-terminal peptide by the PDZ82 Structure 22, 82–93, January 7, 2014 ª2014 Elsevier Ltd All rightsbinding cleft is the core of the interaction, conferring critical
target specificity. As a result, the underlying sequence:affinity
relationships are essential to understand connectivity in PDZ-
mediated protein networks.
To identify the binding preferences of individual domains, early
studies compared the sequences of known binding partners and
highlighted the importance of the amino acids at the P0 (extreme
C terminus) and P2 positions (e.g., Songyang et al., 1997). High-
throughput screens of phage-display and peptide-array libraries
have since revealed more complex ‘‘motifs’’ involving varying
combinations of up to seven C-terminal residues, consistent
with stereochemical interactions observed in individual com-
plexes (Doyle et al., 1996; Laura et al., 2002; Schultz et al.,
1998; Skelton et al., 2003; Stiffler et al., 2007; Tonikian et al.,
2008). Furthermore, although few motifs have been investigated
beyond the P6 position, biochemical and structural studies
have identified affinity contributions and stereochemical con-
tacts extending as far as the P10 position (reviewed in Luck
et al., 2012).
Even with extended motifs, PDZ binding motifs on average
constrain fewer than four of the potential interacting residues
and often accommodate similar residues at a given position (Da-
vey et al., 2012). As a result, PDZ domains are frequently promis-
cuous, binding multiple target proteins and sharing targets with
other PDZ domains. This is illustrated by a set of PDZ proteins
that regulate the intracellular trafficking and localization of the
cystic fibrosis transmembrane conductance regulator (CFTR):
the CFTR-associated ligand (CAL) and the NHE3 regulatory fac-
tor proteins NHERF1 and NHERF2 (Cheng et al., 2002; Guerra
et al., 2005; Wolde et al., 2007). Consistent with shared target
specificity, sequence alignments revealed overlapping motifs
at the P0 and P2 positions, and sequence optimization in the
four C-terminal residues led to only 10-fold selectivity for the
CAL PDZ (CALP) domain (Vouilleme et al., 2010). Using a pep-
tide-array approach to extend the sequence iteratively toward
the N terminus, we engineered a CALP inhibitor (iCAL36;
sequence ANSRWPTSII) with 170-fold selectivity (Cushing
et al., 2010; Vouilleme et al., 2010).
Here we characterize the interaction of the CAL PDZ domain
with theseN-terminal (‘‘upstream,’’ i.e., P4 to P9) binding deter-
minants and with the P1 and P3 side chains. Although not
captured by sequence alignment techniques, they act as bindingreserved
A B Figure 1. Sequence Determinants of CAL
PDZ Binding and CAL/NHERF Specificity
(A) WebLogo analysis (Crooks et al., 2004)
of the top 100 sequences that bound CALP
in a 6223HumLib peptide array experiment
reveals clear preferences at the P0 and P2
positions, similar to the short, degenerate
binding motifs seen with the NHERF PDZ
domains (Figure S1A). The C-terminal residue
(P0) position is labeled 0; adjacent residues are
1, 2, etc.
(B) For each PDZ domain, free energies of
binding (kcal/mol) were calculated from the
binding affinities determined by FP for ten different iCAL36/CFTR chimeric peptide sequences (Table 1). The number of intersection points in
pairwise free-energy plots (Figure S2) were tabulated to reveal rank-order exchanges as a function of sequence.
Structure
Affinity Modulators in CAL PDZ Binding‘‘modulators’’ for each domain, exerting a modest influence indi-
vidually, but a powerful impact collectively. Crystallographic anal-
ysis of 13newCALP:peptidecomplexesspanningawide rangeof
affinities reveals an accommodating pharmacophore binding
model. In-depth stereochemical and substitutional array analysis
provides clues to the identification of preferences that remainhid-
den fromalignmentmotifs. Thesemodulatory effects facilitate the
identification of high-affinity binding sequences and contribute to
inhibitor specificity in the context of CFTR trafficking.
RESULTS
Sequence Alignments Identify only Core Binding Motifs
for CAL and NHERF
Based on the demonstrated contributions of upstream residues
to the selectivity of our engineered iCAL36peptide,weattempted
to identify extended binding motifs for the CAL and NHERF PDZ
domains. We performed WebLogo analysis of all ten C-terminal
positions in peptides identified by screening a 6223HumLib
array (Cushing et al., 2008) with CALP or with the NHERF1 and
NHERF2 PDZ1 and PDZ2 domains (N1P1, N1P2, N2P2, and
N2P2, respectively). However, the results (Figure 1A; Figure S1A
available online) did not highlight any significant upstream
preferences outside the previously examined core residues P0
to P3 (Roberts et al., 2012; Vouilleme et al., 2010).
Weak secondary CALP preferences are observed at a few
positions (e.g., S > E > V at P3; Figure 1A). To test the robust-
ness of such signatures, we calculated motifs using a varying
number of input sequences, and observed that both the rank
order and stereochemical nature of the residues changed. For
example, at P3, the top ten CALP-binding sequences yielded
the pattern E > S > T, whereas the top 50 sequences yielded
S > I >Q (Figure S1B). Furthermore, while the top ten CALP-bind-
ing sequences showmodest signals, e.g., for Arg at P1 or Ser at
P7, these grow progressively weaker or shift with the addition of
more sequences (Figures 1A and S1B). To evaluate the possibil-
ity of correlated binding requirements across multiple ligand po-
sitions, we reprobed our top 100 sequences using the MUltiple
Specificity Identifier (MUSI) program, which uses both single
and multiple position weight matrices to determine specificity
patterns (Kim et al., 2012a). Overall, the results again confirm
the highly degenerate CALP binding motif originally seen at the
P0 and P2 positions (Figure S1C).
Similar patterns are observed for the NHERF domains (Fig-
ure S1A). In some cases, secondary preferences seen at the P3Structure 22position (e.g.,S>E>T forN1P2andE>S>D forN2P2) areslightly
stronger than those observed for CALP. At least in the case of the
N2P2 domain, the presence of acidic residues is broadly consis-
tent with a P3 preference for Asp reported in earlier phage-
display studies (Tonikian et al., 2008). However, as for CALP, no
strong signatures were observed upstream of P3.
Chimeric Peptides Reveal Positive and Negative Affinity
Modulators
Although our experience suggested that residues outside the
P0/P2 motif positions significantly enhanced binding selectivity
of iCAL36 for CAL versus NHERF domains, we had not focused
on CALP affinity per se, which changed relatively little in the later
stages of iCAL36 sequence engineering (Vouilleme et al., 2010).
Given the lack of upstreambindingmotifs, we decided to explore
the free-energy contributions of non-motif residues using nested
sets of chimeric peptides based on reference sequences with
both high (iCAL36; Ki = 23 mM) and low (CFTR; Ki = 420 mM)
affinity for the CALP domain (Amacher et al., 2013). Using fluo-
rescence polarization (FP) competition experiments, we deter-
mined Ki values for each of the chimeric peptides binding to
CALP (Table 1). CALP has modest preferences for an 9ANSR6
sequence over 9TEEE6 (iCAL36VQDTRL versus CFTR), Trp over
Val at P5 (iCAL36QDTRL versus iCAL36VQDTRL), and Gln over Pro
at P4 (iCAL36 versus iCAL36Q4). A positive CALP preference for
a P1 Arg is also suggested by the 5-fold higher affinity of the
iCAL36TRL sequenced compared to iCAL36L and the approxi-
mate equivalence of the Ser/Thr motif at P2 (Vouilleme et al.,
2010). However, the most significant effect is seen at P3.
Replacing 5WPT3 with 5VQD3 in iCAL36VQD3 dramatically
reduces CALP affinity (Ki > 1 mM). Because neither the P
5 nor
P4 substitutions account for such a large effect, we synthesized
a CFTR peptide with a single substitution at P3. CFTRT3
(TEEEVQTTRL; Ki = 18 mM) binds 23-fold more tightly than the
native CFTR sequence (Table 1).
To test the hypothesis that non-motif residues also affect
NHERF1 and NHERF2 affinities, we measured the binding con-
stants of the chimeric peptides for each of the four PDZ domains
(N1P1, N1P2, N2P2, and N2P2, respectively) in FP displacement
assays (Table 1). The NHERF PDZ domains bind the CFTR and
iCAL36 peptides with high affinity for CFTR (Ki < 2 mM) and low
affinity for iCAL36 (Ki > 1 mM; Amacher et al., 2013). Among
these domains, substitutions at P1 (iCAL36TRL versus iCAL36L),
P3 (CFTRT3), P
4 (iCAL36Q4), and P
6P9 (CFTR versus
iCAL36VQDTRL) each affect individual Ki values., 82–93, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 83
Table 1. FP Binding Affinities of CALP and NHERF PDZ Domains for iCAL36/CFTR Chimeric Peptides
Ki (mM)
Peptidea Sequenceb CALP CALP-E317A N1P1 N1P2 N2P1 N2P2
iCAL36TRL ANSRWPTTRL 4.5 ± 0.8 2.2 ± 1.2 8.0 ± 1.4 110 ± 10 8.7 ± 3.1 16.5 ± 3.9
iCAL36Q4 ANSRWQTSII 14.8 ± 3.5 ND 280 ± 100 >1,000 300 ± 100 450 ± 150
CFTRT3 TEEEVQTTRL 18 ± 5.5 15.1 ± 2.0 0.76 ± 0.51 4.6 ± 1.6 1.3 ± 0.4 0.45 ± 0.25
iCAL36c ANSRWPTSII 22.6 ± 8.0 15.1 ± 2.1 >1,000 >1,000 >1,000 >1,000
iCAL36L
c ANSRWPTSIL 23.6 ± 2.2 ND 230 ± 100 >1,000 76.8 ± 1.6 530 ± 120
iCAL36QDTRL ANSRWQDTRL 56.2 ± 5.6 16.2 ± 3.5 1.5 ± 0.2 6.7 ± 2.4 3.1 ± 1.4 1.1 ± 0.6
iCAL36VQDTRL ANSRVQDTRL 230 ± 30 140 ± 40 2.5 ± 0.3 6.5 ± 2.3 3.8 ± 1.4 0.94 ± 0.42
CFTRc TEEEVQDTRL 420 ± 80 64.7 ± 1.8 0.47 ± 0.2 1.8 ± 0.5 0.83 ± 0.33 0.07 ± 0.05
CFTRI
c TEEEVQDTRI 490 ± 120 ND 10.7 ± 2.8 39.8 ± 1.0 19.1 ± 2.9 2.5 ± 0.43
iCAL36VQD3 ANSRVQDSII >1,000 770 ± 50 >1,000 >1,000 >1,000 420 ± 120
ND, value was not measured.
aSubstitutions noted in subscript; the final substituted position is C terminal unless numbered.
bBold indicates residue(s) from the CFTR sequence; non-bold indicates residues from iCAL36.
cValues previously reported in Amacher et al., 2013.
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to contribute to PDZ inhibitor selectivity, we developed an
approach to identify substitutions that switched rank order of
affinity. We first plotted the binding free energies for the series
of peptides along a vertical axis for each domain. When placed
side-by-side for a given pair of PDZ domains, with straight line
connections between the values for each peptide, rank-order
switches appear as points of intersection (Figure S2). Compared
to each NHERF PDZ domain, the CALP affinities exhibit 19–25
pairwise affinity crossovers (Figure 1B) that presumably account
for the engineered selectivity of iCAL36. Thus, although the CAL
and NHERF binding motifs fail to highlight preferences at P-1,
and P-3 through P-9, these residues are capable of ‘‘modulating’’
both the affinity and selectivity of peptides for these PDZ
domains. Furthermore, despite high sequence identity (58%–
72%) between the NHERF PDZ domains, pairwise comparisons
reveal two to six crossovers (Figure 1B), suggesting potential
non-motif contributions to selectivity even in this tightly related
cluster.
All Six C-Terminal Positions Form Side-Chain-
Dependent Interactions
Despite the absence of motif signatures at four of the six resi-
dues from P0 to P5, each residue directly contacts the surface
of the CALP binding site, as illustrated in Figure 2A for one of
the two protomers in our previously published CALP:iCAL36
structure (Amacher et al., 2013). Corresponding contact sur-
faces on the peptide are highlighted by comparison of the sol-
vent-accessible surface of the bound peptide in the absence
(Figure 2C) and presence of the CALP domain (Figure 2D).
The non-motif contacts also represent potentially significant
stereochemical constraints. The fraction of solvent-accessible
surface area (SASA) buried serves as an interaction index (IPDZ)
that gauges the extent of side-chain engagement at each posi-
tion along the backbone (Figure 2B). At the non-motif position
P5, IPDZ values (0.87 and 0.63 for the A and B protomers,
respectively) are comparable to those for the motif residue P-2
(0.73 and 0.64). The other side chains exhibit IPDZ values ranging
from 0.26 to 0.60, and even for residues with lower side chain84 Structure 22, 82–93, January 7, 2014 ª2014 Elsevier Ltd All rightsIPDZ values, several side chain atoms are occluded at least
50% upon CALP docking (atoms colored white in Figure 2D).
Of course, contact mapping cannot by itself distinguish
between favorable and unfavorable binding relationships. It
also does not capture long-range (e.g., electrostatic) interactions
or shifts in the free energy of the unbound state. Nevertheless,
the observed steric interactions are consistent with evidence
that non-motif residues can affect CALP affinity.
Defined CALP Binding Sites Interact with Each Residue
Position
Given the characteristically shallow peptide-binding pocket
of the CALP domain, we wished to determine whether our
substituted peptides adopt significantly variable conformations,
which could complicate stereochemical analysis and obscure
modulator preferences in sequence alignments. To address
this point, we crystallized and solved the structures of CALP
bound to four chimeric iCAL36/CFTR peptides, selected to cover
a range of affinities: iCAL36TRL (Ki = 4.5 mM), iCAL36Q4 (Ki =
14.8 mM), iCAL36QDTRL (Ki = 56.2 mM), and iCAL36VQD3 (Ki >
1 mM). To further explore sequence and conformational space,
we also crystallized CALP bound to two additional low-affinity
binding partners with unrelated sequences. HPV E6 viral onco-
protein C-terminal peptides have been studied in complex
with other PDZ domains with nuclear magnetic resonance and
X-ray crystallography (Charbonnier et al., 2011; Liu et al., 2007;
Mischo et al., 2013; Zhang et al., 2007). Here, we generated
CALP complexes with the decameric E6 C-terminal peptides
from HPV16 (SSRTRRETQL) and HPV18 (RLQRRRETQV; Jeong
et al., 2007; Pim et al., 2012), with Ki values of 340 ± 70 mM and
490 ± 20 mM, respectively.
Structure determination and refinement protocols were de-
signed to avoid phase bias (Table S1; Figures S3 and S4). Final
data and refinement statistics are shown in Table 2. In general,
the iCAL-based structures are very similar. When the PDZ back-
bone atoms of each structure are aligned to the CALP:iCAL36 B-
protomer, they exhibit an average root-mean-square deviation
(rmsd) value of 0.34 ± 0.09 A˚, with a maximum of only 0.52 A˚
(B-protomer of CALP:iCAL36TRL). Visually, the superposition ofreserved
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Figure 2. Six Peptide Positions Interact with the CALP Binding Cleft
(A) The van der Waals surface of the CALP protein is shown together with the
bound iCAL36 peptide (stick figure), with individual residues labeled and
colored by position. The CALP surface (cyan) is colored at contact sites
according to the closest peptide residue: P0 Ile (red), P1 Ile (purple), P2 Ser
(gray), P3 Thr (orange), P-4 Pro (yellow), P5 Trp (blue), P6 Arg (green), P7
Ser (black), P8 Asn (pink), and P9 Ala (forest green).
(B) The peptide side-chain interaction index (IPDZ) is shown as a function of
residue position for the peptides interacting with the A- (gray), and B- (black)
CALP protomers of the asymmetric unit.
(C and D) The van der Waals surface of the bound conformation of the iCAL36
peptide is shown in the same perspective as in (A, left) and following rotation by
135 around the vertical axis (right). The surface is colored by residue as in (A).
To illustrate the surface contacted by CALP, individual atoms with IPDZ values
> 0.5 are colored white in (D), involving residues P0P5.
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Affinity Modulators in CAL PDZ Bindingthese CALP domains (Figure 3A) confirms that the framework of
the binding cleft is largely independent of ligand sequence.
This domain superposition also reveals strong conformational
similarity of the peptides. We first compared the complexes
formed by derivatives of the iCAL sequence, including the
chimeric peptides described above, as well as earlier structures
of iCAL36 and iCAL36L (Amacher et al., 2013). Despite widely
varying binding affinities, all peptide co-complexes reflect
canonical Class I PDZ domain-target interactions: the P0 residue
with the carboxylate-binding loop, the P2 residue with His349,
and conserved b sheet interactions (Figure 3B). Pairwise com-
parisons of the peptides reveal Ca variations less than 1.1 A˚ for
the P0 to P3 positions, and up to 4.4 A˚ for the P4 and P5
positions. These latter variations may partially reflect conforma-
tional changes due to differential crystal packing (Figure S3), but
the side chains at each position still contact relatively similar sur-
faces on CALP. Thus, even the substitution of half of the residues
in the peptide has only a limited effect on the stereochemical
environment experienced by the side chain at a given position
along the backbone.
Comparison of iCAL36with the HPV E6 peptides also revealed
similar peptide backbone conformations, despite very low
sequence similarity (Figure 3C). Thus, in all of our structures,
the side chains at a given peptide position are oriented similarly,
contacting a common CALP local environment. As a result, weStructure 22can extend previous models (e.g., Kang et al., 2003) to define
a pharmacophore model in which positions P0 to P5 each
interact with cognate sites S0 to S5 (Figure 3C). According to
thismodel, each CALP site exhibits a characteristic set of stereo-
chemical constraints that favor the binding of a corresponding
subset of complementary amino acid(s). If the constraints are
stringent, they may be present in enough sequences to appear
as part of a motif. If they are more accommodating, they may
not, but may still contribute to affinity as modulators.
Positional SubAna Analysis Confirms Multiple
Modulatory Residues
As a further test of the idea that each peptide side chain contacts
a defined stereochemical environment relatively independent
of sequence context, we performed substitutional analysis
(SubAna) using peptide arrays derived from a variety of starting
sequences. Each SubAna array contains a single peptide
sequence with all 20 natural L-amino acids individually
substituted at each position along the chain (Boisguerin et al.,
2007). We chose to use SubAnas based on ten starting se-
quences that encompassed a number of different CALP-binding
attributes (sequences are described in detail in Figure S5).
Except for the artificial iCAL36 sequence, these peptides are
derived from endogenous proteins, include known interacting
partners (Cheng et al., 2002; Wente et al., 2005), cover a wide
range of affinities for CALP (Cushing et al., 2008), and provide
a variety of binding motif residue combinations (S/T at the P2
position, I/L/V at the P0 position) for comparison. Furthermore,
while the amount of protein bound is measured at a single con-
centration under nonequilibrium conditions, we can qualitatively
compare trends across arrays (Boisguerin et al., 2011). To
compare positional preferences across the full set of peptides,
we separated each SubAna array into six strips, corresponding
to the residues from P0 to P5, and then aligned all of the strips
for P0, all of the strips for P1, etc. The resulting collage (Figure 4)
shows the variability of side chain preference(s) at a given posi-
tion. Consistent selective preferences at the P0 and P2 posi-
tions reflect their status as motif residues, largely independent
of peptide context.
At the other positions, a more heterogeneous picture
emerges, consistent with the lack of motif constraints observed
previously (Figure 1B). A residue may be favored for certain
sequences, and disfavored for others. For example, a P4 Phe
residue appears to be strongly favored for CFTR (row 7) and
other sequences, while disfavored for VIPR2 (row 9). However,
despite this variability, certain trends are observed that apply
to most or all sequences. For example, our positional arrays
confirm positive preferences for a P1 Arg and for a P5 Trp
residue. They also reveal negative preferences, including P3
Asp (Figure 4), consistent with the affinity difference observed
between CFTR and CFTRT3 (Table 1). CALP also appears to
disfavor a Gly or Pro at P1 and Pro at P3.
Single Substitutions at P–5 Modulate Binding Affinity
To investigate the stereochemistry of preferential accommoda-
tion of a modulator residue, we focused on the impact of single
residue substitutions in iCAL36 at the P5 position. Competition
FP experiments confirm a range of affinities for P5-substituted
peptides (Table 3). The Leu- and Tyr-substituted peptides bind, 82–93, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 85
Table 2. Data Collection and Refinement Statistics for CALP Co-Crystals with iCAL36/CFTR Chimeric Peptides
iCAL36Q4
CALP
iCAL36TRL
CALP
iCAL36VQD3
CALP
iCAL36QDTRL
CALP
iCAL36QDTRL
CALP-E317A
HPV16 E6
CALP
HPV18 E6
CALP
Data collection
Space group (number) P 21 21 21 (19) P 1 (1) P 21 (4) P 63 2 2 (182) P 63 2 2 (182) P 21 (4) P 21 (4)
Unit cell dimensions
a,b,c (A˚) 36.0,47.7,98 30.8,50.2,55.2 36.3,48.8,54.9 61.6,61.6,97.6 61.8,61.8,97.4 33.1,48.4,52 33.2,48.0,52.9
a,b,g () 90,90,90 68.8,75.8,87.9 90,92.8,90 90,90,120 90,90,120 90,101.6,90 90,102.0,90
Resolution (A˚)a 19.9–1.48
(1.58–1.48)
19.3–1.75
(1.79–1.7)
19.6–1.90
(2.03–1.9)
19.7–1.50
(1.58–1.5)
19.1–1.80
(1.85–1.8)
19.4–1.80
(1.90–1.8)
19.3–1.34
(1.42–1.34)
Rsym (%)
b 5.9 (45.0) 4.5 (37.2) 6.5 (36.0) 4.9 (61.5) 11.0 (61.7) 5.9 (52.3) 3.8 (26.5)
I/sI
c 34.60 (6.93) 15.48 (2.60) 15.58 (3.59) 49.46 (6.32) 26.01 (6.53) 20.37 (3.16) 36.69 (7.53)
Completeness (%) 99.7 (99.2) 94.8 (91.1) 99.6 (99.5) 99.9 (100.0) 99.9 (100.0) 99.4 (98.1) 94.2 (77.8)
Refinement
Total no. of reflections 28,816 30,585 15,162 18,179 10,780 14,953 34,482
Reflections in test set 1,460 1,493 763 920 560 758 1,729
Rwork
d/Rfree
e (%) 18.1/20.9 17.2 /22.1 17.9/22.7 19.7/22.1 18.1/22.1 18.3/22.3 17.2/18.1
Number of atoms
Protein 1,467 2,927 1,426 774f 772f 1,431 1,507
Water 180 267 141 69 69 147 258
Ramachandran plotg (%) 96.8/3.2/0/0 95.6/4.4/0/0 98.0/2.0/0/0 97.3/2.7/0/0 100/0/0/0 96.6/3.4/0/0 97.4/2.6/0/0
Bav (A˚
2)
Protein 13.27 18.96 22.38 19.36 16.32 23.40 9.86
Solvent 24.62 28.73 31.27 30.03 27.43 31.13 23.10
Bond length rmsd (A˚) 0.006 0.006 0.007 0.007 0.008 0.007 0.007
Bond angle rmsd () 1.078 1.006 1.097 1.169 1.203 1.064 1.167
aValues in parentheses are for data in the highest-resolution shell.
bRsym =
P
h
P
i jIðhÞ  IiðhÞj=
P
h
P
i IiðhÞ , where Ii(h) and I(h) values are the i-th and mean measurements of the intensity of reflection h.
cSigAno= jFð+ Þ-Fð-Þj=s.
dRwork =
P kFobsjh  jFcalckh=
P jFobsjh , h e {working set}.
eRfree is calculated as Rwork for the reflections h e {test set}.
fIncluding sulfocysteine at position 319 (see Figure S4).
gCore/allowed/generously allowed/disallowed.
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Affinity Modulators in CAL PDZ BindingCALP with Ki % 100 mM, whereas the Ala- and His-substituted
peptides each showR 10-fold losses in affinity. A P5 His side
chain results in the weakest affinity of the set, at 450 mM, compa-
rable to that of CALP:CFTR binding.
All six peptides were crystallized in complex with CALP. Struc-
tures were determined using the methods described above for
the chimeric peptide complexes (Table S1 and Supplemental
Experimental Procedures), with data and refinement statistics
reported in Table 4. For structural comparisons, we aligned the
main-chain atoms of the P5-substituted peptide:CALP com-
plexes, using CALP:iCAL36 as a reference. Because the super-
position of chimeric peptides had shown slight variations at the
C-terminal core (positions P0 to P3), we first compared the po-
sitions of the Ca atoms in these residues. In this region, the rmsd
for the P5-substituted peptides is less than the coordinate error
(Figure 5A). There is a larger degree of variability at the P-4 and
P5 positions (% 3 A˚), but the side chains remain clustered, again
suggesting that modulations in binding affinity at the P5 residue
are due to local binding effects, not to large-scale alterations of
residue interactions (Figure 5A).
As seen for the chimeric peptides (Figure 3C), all P5 residues
interact with S5, comprised of the same His309-Gly310-Val31186 Structure 22, 82–93, January 7, 2014 ª2014 Elsevier Ltd All rightshydrophobic ledge that interacts with the P5 Trp in iCAL36
(Amacher et al., 2013). However, despite this shared environ-
ment (Figure 5B; Figure S6), there is no obvious correlation of
the observed range of affinities with stereochemical parameters,
including electrostatic interactions or buried surface area met-
rics. For example, although the highest affinity peptide (Trp) is
associated with the largest contact surface area, the second
highest-affinity peptide (Leu) has a smaller contact surface
than the significantly weaker His, Phe, or Tyr peptides (Table 3).
However, more sophisticated computational approaches have
shown promise in capturing CALP affinity determinants: the
K* algorithm used energy minimization of conformational
ensembles to estimate partition functions for the free and
bound partners. Interestingly, eight of the top 11 K*-designed
sequences contained a P1 Arg, including kCAL01 (WQVTRV),
which has the highest affinity observed to date for a hexameric
sequence (Roberts et al., 2012).
Electrostatic Potential Contributes to Modulator
Preferences at P–1 and P–3
Our SubAna comparisons (Figure 4) also revealed prom-
inent modulatory preferences at P1 (favoring Arg) and P3reserved
His349
Leu299
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-20
-3
-4
-5
S S
S-20
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S S
S
-1 -3
-5
290
300
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320
330
340
350
360
2.8 Å
2.9 Å
2.7 Å
Figure 3. Peptide Residues Lie in Distinct CALP Binding Sites
(A) Ca traces are shown for CALP protomers from each of four different space-groups (Table S1), following superposition of main-chain atoms on the B-protomer
of CALP:iCAL36. Traces are colored by space group: P212121 (black), P1 (green), P21 (cyan), and P6322 (pink). Every tenth residue is indicated with a black circle
and residue number. The tight clustering reveals no gross conformational changes in the PDZ domain based on lattice packing, peptide sequence, or affinity. See
also Figure S3.
(B) Following superposition of PDZmain-chain atoms, chimeric iCAL36/CFTR peptides (stick figures) bind CALP (cartoon, gray) in similar conformations, despite
sequence and affinity differences (Table 1). Characteristic PDZ hydrogen bonds are shown as dashed lines, including carboxylate interactionswith residuesGly300
and Leu299 and a P-2 interaction with His349 (stick figures). iCAL36 (green carbons) and the highest (iCAL36TRL; cyan) and lowest (iCAL36VQD3; orange) affinity
peptides are highlighted for reference. Other peptides (gray) include iCAL36QDTRL, iCAL36Q4, iCAL36L, HPV16 E6, and HPV18 E6. See also Figures S8A–S8G.
(C) Following superposition of PDZ main-chain atoms, bound peptide conformations are shown for C-terminal peptides derived from the HPV16 (black) and
HPV18 (pink) E6 proteins together with iCAL36 (green). Binding sites are shown schematically for each position (S0, S1, etc.). Noncarbon atoms are colored by
element (red = O, blue = N).
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result, we investigated the electrostatic environment of the cor-
responding binding sites. Rendered at 10 kBT/e, the CALP van
derWaals surface potential reveals distinct positive and negative
surfaces on opposite sides of the peptide-binding cleft (Fig-
ure 5C; Figure S7A). In the CALP:iCAL36QDTRL structure, both
the P1 Arg and the P3 Asp residues point toward a ridge of
negative potential, comprised of the b2, b3, a1, and b4 second-
ary structure elements, as well as connecting loops. This elec-
trostatic environment could thus account for both of these
modulator preferences (Figure 5D).
Specifically, the P1 Arg is hydrogen-bonded with Gln322,
facilitating a favorable interaction between the positively
charged arginine guanidino group and an area of negative poten-
tial (Figure 5D). In contrast, the negatively charged P3 Asp side-
chain carboxylate is positioned directly adjacent to the negative
potential surface, creating a Coulombic repulsion, even though
the nearest charged residue is > 5 A˚ away. To test the role of
this side chain in determining modulator preferences, we
expressed and purified a CALP-E317A mutant. Unfortunately,
a crystal structure of the mutant (Table 2; Figures S7B and
S7C, and Supplemental Experimental Procedures) showed
that the region of negative electrostatic potential was only
modestly attenuated relative to wild-type (Figure 5C, insets).
Correspondingly small (< 7-fold) effects were observed on pep-
tide binding affinities (Table 1).
However, a clearer picture is provided by analysis of the
NHERFPDZ domains, which do not share the charge distribution
of CALP. For example, in N1P1, the residue corresponding to
CALP-Glu317 is Leu41, a nonpolar residue. Consistently, all four
NHERF1/2 PDZ domains make favorable hydrogen bonds with
the P3 Asp, which is in a positive environment (Figures S7D–
S7G). Indeed, in contrast to the dramatic increase in binding
affinity for CALP upon substitution of the P3 Asp to Thr,
CFTRT3 affinity was 2- to 6-fold weaker than that of CFTR forStructure 22each of the NHERF1/2 PDZ domains (Table 1), confirming their
modest preference for the P3 Asp.
Using Modulator Preferences to Identify High-Affinity
Sequences for CAL
Lastly, we wished to evaluate the ability of modulator prefer-
ences to improve our classification of peptide affinities for the
CALP domain. The human deca-C-terminome, the set of C-ter-
minal decapeptides for all 84,888 protein isoforms listed in the
UniProt database (UniProt Consortium, 2012), contains a total
of 57,632 unique sequences—Of these sequences, 2,197
conform to the CALP binding motif (Figure 6A). However,
CALP only weakly binds some of the peptide sequences that
satisfy its motif, including iCAL36VQD3 and the CFTR C terminus
(Table 1), and others previously tested (Cushing et al., 2008;
Roberts et al., 2012).
To detect candidate high affinity sequences, we applied the
positive modulator preferences at P-1 and P-5. Of the 2,197 motif
sequences, 141 and 36 contain an Arg and a Trp side chain,
respectively (Figure 6B). Only four sequences contain both of
our positive modulator preferences. Although they may not be
physiological partners, all have CALP affinities better than or
comparable to previously reported endogenous CALP ligands
(Cushing et al., 2008): insulin-like growth factor-binding protein
3 receptor (TM219_HUMAN; RESHWSRTRL; Ki = 29 ± 8 mM),
semaphorin 4G isoform 3 (SEM4G_HUMAN; PHSPWSFSRV;
Ki = 46 ± 14 mM), histone H4 transcription factor (HINFP_
HUMAN; CGCSWFATRV; Ki = 46 ± 24 mM), and proteasome
subunit beta type-9 (B4DZW2_HUMAN; GFETWEGSRL; Ki =
120 ± 60 mM). Moreover, the proteasomal sequence contains a
P3 Gly residue (underlined), which has a negative influence in
the positional arrays (Figure 4) and thus may account for its
somewhat lower affinity. Likewise, endogenous targets contain-
ing the strongest negative modulator (Asp at P3) are among the
weakest CALP interactors (Figure 6B). Taken together, our data, 82–93, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 87
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Figure 4. Position-Specific Peptide Arrays
Reveal Modulator Preferences for CALP
SubAna arrays of ten peptides are clustered by
residue position, with each row labeled according
to the background sequence of the source array
(see key for sequence information). The WT resi-
dues are listed to the right of each row. Residues in
the initial sequence are substituted by all 20 L-
amino acids, as indicated at top (see text). The
motif positions P0 and P2 reveal clear preferences
for only a few residues. Positive modulator pref-
erences are seen as consistently stronger binding
thanWT following substitution of e.g., Arg at P1 or
Trp at P5, independent of the background pep-
tide sequence. Negative preferences are also seen
as consistently weaker binding compared to WT,
e.g., following substitution of Gly at P1 or Asp at
P3. See also Figure S5.
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affinity of candidate CALP-binding sequences.
DISCUSSION
As illustrated by the weak CALP binding of C-terminal peptides
from the known endogenous interactors CFTR and b-catenin
(Cushing et al., 2008), there is abundant evidence that SLiM pep-
tide affinity is not always the sole determinant of in vivo interac-
tions, which also depend onmolecular and cellular context (Luck
et al., 2012). Nevertheless, PDZ:peptide binding remains a key
element of specificity. Thus, deciphering the relationship be-
tween peptide sequence and PDZ affinity is a core requirement
for understanding the networks of interactions formed by these
ubiquitous protein-protein interaction domains. Over the past
15 years, studies have identified binding motifs and contacts
from the C terminus to the P10 position (Appleton et al., 2006;
Luck et al., 2012; e.g., Skelton et al., 2003; Smith and Kortemme,
2010; Thomas et al., 2008).
However, recent evidence suggests that PDZ sequence:
affinity relationships can involve either more or fewer residues
than indicated by motifs defined by alignments of high-affinity88 Structure 22, 82–93, January 7, 2014 ª2014 Elsevier Ltd All rights reservedsequences. For example, while the Lin-7
homolog A (Lin7A) PDZ domain exhibits
a highly selective motif with up to 6 deter-
minants (Tonikian et al., 2008), fewer than
four of these motif constraints are satis-
fied in any single Lin7A target sequence
(UniProt Consortium, 2012), and no
annotated human C-terminal sequence
matches the complete Lin7A PDZ binding
motif. In contrast, although the binding
motif for the CAL PDZ domain is highly
degenerate (Figure 1B; Figure S1A),
many motif-compatible sequences actu-
ally have negligible affinity for the domain
(Roberts et al., 2012).
Overall, it appears that PDZ domains
achieve sufficient binding affinity by har-
nessing strong free energy contributionsat a few anchor positions, supplemented by additional stereo-
chemical interactions that may involve either additional motif
constraints or non-motif ‘‘modulator’’ residues. Structural com-
parisons suggest that such modulator preferences reflect rela-
tively loose pharmacophore sites, each of which engages the
side chain at a particular position (Figure 3C). In fact, although
only a limited number of other PDZ domains have been co-crys-
tallized with more than one peptide ligand (e.g., Babault et al.,
2011; Grembecka et al., 2006; Kang et al., 2003; Nomme et al.,
2011), as for CALP, superpositions in these cases also suggest
that each domain imposes a characteristic binding conformation
on its ligands, and can thus define a set of domain-specific
sequence preferences (Figure 3B; Figure S8).
Whether these preferences are readily captured in alignment
motifs depends on a number of factors, including the stringency
of the preference itself, as well as the nature of the experiment,
limitations of the technique (e.g., number of sequences tested),
and the baseline affinity of the domain for the peptide backbone.
In many cases, preferences are subtle and lead only to marginal
enrichment relative to random sequences. For example, our P5
residue analysis suggests that all seven substituted amino acids
(Trp/Leu/Tyr/Phe/Val/Ala/His) could have been found in peptides
Table 3. CALP Binding Affinities for P-5-Substituted iCAL36
Peptides
Ki (mM) Contact Surface Area
a (A˚2)
Peptide Sequenceb CALP Peptide P5 Position
iCAL36c ANSRWPTSII 22.6 ± 8.0 533.4 109.5
L-iCAL36 ANSRLPTSII 68 ± 20 492.2 73.9
Y-iCAL36 ANSRYPTSII 85.3 ± 1.5 518.2 99.6
F-iCAL36 ANSRFPTSII 110 ± 20 506.9 86.6
V-iCAL36 ANSRVPTSII 190 ± 40 485.8 66.4
A-iCAL36 ANSRAPTSII 275 ± 80 461.9 42.5
H-iCAL36 ANSRHPTSII 450 ± 10 505.5 79.2
aContact surface area for each P-5 position includes all atoms of the res-
idue.
bSubstitutions at the P5 position are indicated in bold.
cValues previously reported in Amacher et al., 2013.
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Affinity Modulators in CAL PDZ Bindingthat were included in the binding motif analysis, as the
substituted iCAL peptides all bind CALP with affinity greater
than that of CFTR, a top 100 sequence hit. This variability may
reflect the attenuated specificity of surface-exposed stereo-Table 4. Data Collection and Refinement Statistics for CALP Co-Cr
A-iCAL36 L-iCAL36 V-iC
Data collection
Space group P 21 21 21 P 21 21 21 P 21
Unit cell dimensions
a,b,c (A˚) 36.7,47.8,97.6 36.2,47.6,97.3 36.7
a,b,g () 90,90,90 90,90,90 90,9
Resolution (A˚)a 18.5–1.14
(1.19–1.14)
34.0–1.2
(1.24–1.2)
19.7
(1.54
Rsym (%)
b 11.6 (39.3) 6.3 (51.5) 6.8 (
I/sI
c 10.14 (3.99) 20.98 (4.24) 16.7
Completeness (%) 99.4 (99.9) 99.9 (99.9) 98.1
Refinement
Total no. of reflections 63,011 53,398 30,1
Reflections in the test set 3,144 2,674 1,51
Rwork
d/Rfree
e (%) 18.5/19.5 18.9/20.1 17.9
Number of atoms
Protein 1,502 1,483 1,47
Water 236 230 180
Ramachandran plot (%)f 94.8/3.4/0/0 96.6/3.4/0/0 97.3
Bav (A˚
2)
Protein 12.35 12.27 14.8
Solvent 25.17 23.39 27.1
Bond length rmsd (A˚) 0.005 0.006 0.00
Bond angle rmsd () 1.108 1.102 1. 04
aValues in parentheses are for data in the highest-resolution shell.
bRsym =
P
h
P
i jIðhÞ  IiðhÞj=
P
h
P
iIiðhÞ , where Ii(h) and I(h) values are the i-th
cSigAno= jFð+ Þ-Fð-Þj=s.
dRwork =
P kFobsjh  jFcalckh=
P jFobsjh , he {working set}.
eRfree is calculated as Rwork for the reflections he {test set}.
fCore/allowed/generously allowed/disallowed.
Structure 22chemical interactions (e.g., Serrano et al., 1990). Whatever the
source of accommodation, alignments are unlikely to achieve
sufficient enrichment to create an obvious motif constraint.
Negative contributions are particularly difficult to detect robustly
by alignment, since the expected observation frequency of a
‘‘neutral’’ residue is its already low rate of natural occurrence,
associated with a correspondingly high level of random
variability.
Our data (Figure 4) suggest that multisequence substitution
analysis represents an effective extension of mutagenetic ap-
proaches (e.g., Wiedemann et al., 2004) to highlight preferences
that are insufficiently robust or sequence-independent to estab-
lish clear motif signatures. SubAna arrays can also readily detect
negative contributions (e.g., Asp at P3) that have important impli-
cations for the biological specificity of PDZ interactions. The P3
Asp side chain at the C terminus of CFTR significantly limits its
affinity for CAL, which targets CFTR to the lysosome, but not for
NHERF1 and NHERF2, which functionally stabilize CFTR at the
apical membrane (Table 1). Thus, the CFTR sequence at this po-
sition specifically favors interactions with PDZ proteins that pro-
mote endocytic recycling over degradation (Cheng et al., 2002).
This example underscores the potential for modulator resi-
dues to differentially affect interactions with PDZ domains thatystals with P–5-Substituted iCAL36 Peptides
AL36 H-iCAL36 F-iCAL36 Y-iCAL36
21 21 P 21 21 21 P 21 21 21 P 21 21 21
,47.9,97.8 36.2,47.8,98.1 36.2,48.1,97.6 36.2,47.8,97.5
0,90 90,90,90 90,90,90 90,90,90
–1.46
–1.46)
19.5–1.47
(1.58–1.47)
19.6–1.2
(1.26–1.2)
18.5–1.09
(1.15–1.09)
50.4) 9.3 (50.6) 8.4 (47.1) 7.5 (34.5)
1 (3.05) 21.17 (6.39) 13.28 (3.86) 15.57 (4.98)
(88.7) 98.3 (97.2) 98.3 (95.7) 98.2 (92.4)
71 28,702 53,211 70,084
6 1,446 2,658 3,525
/19.5 18.0/20.7 18.5/18.8 18.2/18.8
2 1,428 1,522 1,520
170 227 220
/2.7/0/0 96.6/3.4/0/0 97.4/2.6/0/0 97.3/2.7/0/0
5 9.77 12.20 11.95
1 21.72 24.24 23.52
6 0.006 0.006 0.007
3 1.063 1.107 1.073
and mean measurements of the intensity of reflection h.
, 82–93, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 89
A B
C D
Figure 5. Stereochemical Analysis of Modulator Preferences
(A) The clustering of CALP-boundP-5-substituted iCAL36 peptides (stick figures) is shown followingmain-chain superposition of theCALPB-protomers. Peptides
are colored by sequence: iCAL36 (W; green carbons), F- (red), Y- (black), H- (yellow), A- (cyan), L- (orange), and V- (purple). Rmsd offsets at the P0P3 residues
were within coordinate error, while modest variations were observed at the P4 and P5 positions (black arrow). The largest difference is 3.2 A˚, between the Ca of
the L- and Ca of the A-substituted peptides.
(B) Each substituted P5 side chain (colored stick figure) is shown, as docked against its CALP binding interface (surface, cartoon and stick figure). The residues
that contact the P5 residue (His309, Gly310, and Val311) are labeled in the CALP:F-iCAL36 structure. Each panel is labeled with the P5 residue identity. See also
Figure S6.
(C) The electrostatic potential surface of WTCALP (left) reveals a highly polarized distribution on either side of the peptide binding cleft. The electrostatic potential
surface of CALP-E317A (right) shows a reduced, although still negative, interaction surface for the P3 Asp residue of iCAL36QDTRL (insets). See also Figure S7.
(D) Electrostatic interactions are shown for P1 Arg (left) and P3 Asp (right) residues of the iCAL36QDTRL peptide (stick figure, yellow carbons) bound to CALP
(gray Ca trace). At the top, nearby charged CALP residues are shown (stick figures, green carbons). The P
1 Arg forms a hydrogen bond (dashed line) with Gln314.
The closest charged residue for the P3 Asp is Glu317 (d > 5 A˚). In the lower panels, the corresponding electrostatic potential surfaces are shown (rendered at
10 kBT/e) underscoring the negative electrostatic environments of both the P
1 and the P3 side chains.
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Affinity Modulators in CAL PDZ Bindingshare overlapping motifs. Recent work by a number of groups
suggests that PDZ interactions are a finely tuned product of evo-
lution operating both on the PDZ domains (Ernst et al., 2009;
Kaneko et al., 2011; McLaughlin et al., 2012) and on the target
C-terminal sequences themselves (Kim et al., 2012b). If degen-
erate two- or three-residue motifs were sufficient to determine
target affinity for PDZ domains such as CAL or NHERF, such
evolution would be limited by a very small set of combinatorial
possibilities, as would the engineering of highly selective
sequences. While individual modulator residues may contribute
only modestly to target affinity, collectively they have the poten-
tial to significantly differentiate PDZ specificity profiles. As a
result, characterizing these previously cryptic binding determi-
nants may be critical both for a fuller understanding of PDZ90 Structure 22, 82–93, January 7, 2014 ª2014 Elsevier Ltd All rightsdomain interaction networks and for the development of specific
peptide inhibitors of individual nodes.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The CALP E317A mutant was generated using the Quikchange Lightning
(Agilent Technologies) protocol. The wild-type (WT) and mutant CALP
(Amacher et al., 2011) and NHERF PDZ domains (Cushing et al., 2008) were
expressed and purified as previously described. For fluorescence polarization
(FP) experiments, proteins were dialyzed overnight into storage buffer
(150 mM NaCl; 0.02% [w/v] sodium azide, 25 mM sodium phosphate pH
8.0, 0.2 mM tris[2-carboxyethyl]phosphine [TCEP], 5% [v/v] glycerol). For
CALP crystallization, the protein was stored in GF2 buffer (25 mM Tris,
150 mM sodium chloride, 0.02% [w/v] sodium azide, 0.1 mM TCEP, 0.1 mMreserved
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Figure 6. Impact of Binding Motif and
Modulator Residues on PDZ Binding Speci-
ficity
(A) Evaluation of the number of distinct C-terminal
decamers in the human proteome that satisfy the
CALP binding motif (red residues in example
sequences listed at right).
(B) A schematic pharmacophore model of the
series of side chain-binding sites along the CAL
PDZ cleft is shown, some of which are identified as
bindingmotif residues by high-throughput analysis
(Figure 1A). Positive (green) and negative (red)
preferences are shown at non-motif sites, together
with the frequencies of these residues in the pool
of potential CALP binders. FP displacement titra-
tions confirm the expected affinities for represen-
tative peptides that contain positive (left panel,
green) and negative (right, red) modulator resi-
dues, suggesting that modulators can significantly
restrict the number of binding partners by adjust-
ing the overall affinity balance of the PDZ:target
interaction. See also Figure S8H.
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Affinity Modulators in CAL PDZ BindingATP, 5% [v/v] glycerol; Amacher et al., 2011), prior to dialysis into crystalliza-
tion buffer. Peptides for co-crystallization and FP experiments were synthe-
sized and purified by the Tufts Core Peptide Facility.
Crystallization and Structure Determination
Detailed methods for crystallization and determination of each co-crystal
structure and accession codes are presented in Table S1. Complexes wereStructure 22, 82–93, January 7, 201crystallized, data collected, and structures deter-
mined as previously described (Amacher et al.,
2011, 2013).
Structure Analysis
Electrostatic potential surface calculations and
structure alignments were performed in PYMOL
(DeLano, 2008). The contact surface of each pep-
tide residue was depicted using CHIMERA (Pet-
tersen et al., 2004). SASA, including contact, was
calculated using AREAIMOL (Lee and Richards,
1971), part of the CCP4 suite of programs (CCP4,
1994). Contact surface area for each peptide
residue atom was calculated as [SASA]COMPLEX 
[SASA]ALONE. The Interaction Index (IPDZ) is
defined as the fractional change in solvent acces-
sible surface area upon ligand binding, using the
equation:
IPDZ = 1 SASAcomplex
SASAfree
:
Fluorescence Polarization
Fluorescence polarization assays were performed
as previously described (Cushing et al., 2008;
Vouilleme et al., 2010). Triplicate experiments
were performed, using separate protein and
reporter stock solutions in independent peptide
titrations. The Ki values were determined using
a SOLVER-based least-squares fitting algorithm
in EXCEL, as described previously (Amacher
et al., 2013; Cushing et al., 2008; Vouilleme
et al., 2010). The following reporter peptides
were used: F*-iCAL36 (F*-ANSRWPTSII) for
CALP and E317A CALP; F*-CFTR6 (F*-VQDTRL)for N1P1 and N1P2; and F*-CFTR10 (F*-TEEEVQDTRL) for N2P1 and
N2P2. F* corresponds to a fluorescein group linked to the peptide N terminus
via an amino-hexanoic acid linker. The concentrations used for each PDZ
domain were 1.5 3 Kd, where the Kd values of each PDZ domain for their
respective reporter peptides were: CALP (Kd = 0.97 mM), E317A CALP
(0.61 mM), N1P1 (0.37 mM), N1P2 (1.08 mM), N2P1 (0.32 mM), and N2P2
(0.23 mM).4 ª2014 Elsevier Ltd All rights reserved 91
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The full set of 6223HumLib sequences is described elsewhere (Roberts et al.,
2012; see Supplemental Experimental Procedures). Position-specific SubAna
arrays were generated by juxtaposing data for a given peptide position from a
series of SubAna arrays based on distinct peptide sequences. Individual Sub-
Ana arrays were synthesized and binding analyzed as previously described
(Boisguerin et al., 2007; Vouilleme et al., 2010).
Proteome Analysis of Sequences
The Python scripting language (Van Rossum, 2009) was used to map all occur-
rences of the CALP binding motif and the frequency distribution of individual
modulator preferences in the set of all decameric C-terminal peptides present
in the FASTA file provided by UniProt Knowledgebase release 2012_10
(UniProt Consortium, 2012).
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The Protein Data Bank accession numbers for the coordinates and structure
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